{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:29:12Z","timestamp":1791923352285,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The diagnosis of Waldenstr\u00f6m\u2019s macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress on the diagnostic front, as well as a deeper understanding of the disease biology, which has affected clinical practice. This, together with the increasing variety of tools and techniques available, makes it necessary to have a practical guidance for clinicians to perform the initial evaluation of patients with WM. In this paper, we present the consensus recommendations and laboratory requirements for the diagnosis of WM developed by the European Consortium of Waldenstr\u00f6m\u2019s Macroglobulinemia (ECWM), for both clinical practice as well as the research\/academical setting. We provide the procedures for multiparametric flow cytometry, fluorescence in situ hybridization and molecular tests, and with this offer guidance for a standardized diagnostic work-up and methodological workflow of patients with IgM monoclonal gammopathy of uncertain significance, asymptomatic and symptomatic WM.<\/jats:p>","DOI":"10.1038\/s41375-022-01762-3","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T20:24:43Z","timestamp":1669494283000},"page":"388-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Diagnostics in Waldenstr\u00f6m\u2019s macroglobulinemia: a consensus statement of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia"],"prefix":"10.1038","volume":"37","author":[{"given":"Irene","family":"Dogliotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-5154","authenticated-orcid":false,"given":"Cristina","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-8345","authenticated-orcid":false,"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bagratuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Drandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Gilestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8904-3802","authenticated-orcid":false,"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ka\u0161\u010d\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-5128","authenticated-orcid":false,"given":"Aldo M.","family":"Roccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-3144","authenticated-orcid":false,"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-293X","authenticated-orcid":false,"given":"Falko","family":"Fend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9782-9012","authenticated-orcid":false,"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9711-1502","authenticated-orcid":false,"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/sonc.2003.50082","volume":"30","author":"RG Owen","year":"2003","unstructured":"Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstr\u00f6m\u2019s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia. Semin Oncol. 2003;30:110\u20135.","journal-title":"Semin Oncol"},{"key":"1762_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood."},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia."},{"key":"1762_CR4","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","DOI":"10.1182\/blood.2022015851"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.14196","volume":"175","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenstr\u00f6m Macroglobulinaemia: a Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia. Br J Haematol. 2016;175:77\u201386.","journal-title":"Br J Haematol"},{"key":"1762_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.18036","volume":"197","author":"G Pratt","year":"2022","unstructured":"Pratt G, El-Sharkawi D, Kothari J, D\u2019Sa S, Auer R, McCarthy H, et al. Guidelines on the diagnosis and management of Waldenstr\u00f6m macroglobulinaemia\u2014a British Society for Haematology guideline. Br J Haematol. 2022;197:171\u201387.","journal-title":"Br J Haematol"},{"key":"1762_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/modpathol.2009.34","volume":"22","author":"WG Morice","year":"2009","unstructured":"Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstr\u00f6m\u2019s macroglobulinemia. Mod Pathol. 2009;22:807\u201316.","journal-title":"Mod Pathol"},{"key":"1762_CR8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/leu.2013.124","volume":"28","author":"B Paiva","year":"2014","unstructured":"Paiva B, Montes MC, Garc\u00eda-Sanz R, Ocio EM, Alonso J, de las Heras N, et al. Multiparameter flow cytometry for the identification of the Waldenstr\u00f6m\u2019s clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2014;28:166\u201373.","journal-title":"Leukemia."},{"key":"1762_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.beha.2016.08.024","volume":"29","author":"R Garc\u00eda-Sanz","year":"2016","unstructured":"Garc\u00eda-Sanz R, Jimenez C, Puig N, Paiva B, Gutierrez NC, Rodr\u00edguez-Otero P, et al. Origin of Waldenstrom\u2019s macroglobulinaemia. Best Pr Res Clin Haematol. 2016;29:136\u201347.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1762_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom\u2019s macroglobulinemia, IgM monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific PCR. Blood. 2013;121:2051\u20138.","journal-title":"Blood."},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","volume":"88","author":"M Varettoni","year":"2013","unstructured":"Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;88:2522\u20138.","journal-title":"Blood."},{"key":"1762_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/leu.2013.62","volume":"27","author":"C Jim\u00e9nez","year":"2013","unstructured":"Jim\u00e9nez C, Sebasti\u00e1n E, Chill\u00f3n MC, Giraldo P, Mariano Hern\u00e1ndez J, Escalante F, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia. 2013;27:1722\u20138.","journal-title":"Leukemia."},{"key":"1762_CR14","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","volume":"121","author":"S Poulain","year":"2013","unstructured":"Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121:4504\u201311.","journal-title":"Blood."},{"key":"1762_CR15","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjh.12313","volume":"161","author":"W Willenbacher","year":"2013","unstructured":"Willenbacher W, Willenbacher E, Brunner A, Manzl C. Improved accuracy of discrimination between IgM multiple myeloma and Waldenstr\u00f6m macroglobulinaemia by testing for MYD88 L265P mutations. Br J Haematol. 2013;161:902\u20134.","journal-title":"Br J Haematol"},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","volume":"123","author":"A Mart\u00ednez-Trillos","year":"2014","unstructured":"Mart\u00ednez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, et al. Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123:3790\u20136.","journal-title":"Blood."},{"key":"1762_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/leu.2012.257","volume":"27","author":"N Gachard","year":"2013","unstructured":"Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphomas. Leukemia. 2013;27:183\u20139.","journal-title":"Leukemia."},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637\u201346.","journal-title":"Blood."},{"key":"1762_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00277-017-3207-3","volume":"97","author":"C Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez C, Prieto-Conde MI, Garc\u00eda-\u00c1lvarez M, Alcoceba M, Escalante F, Chill\u00f3n MDC, et al. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Ann Hematol. 2018;97:475\u201384.","journal-title":"Ann Hematol"},{"key":"1762_CR20","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","volume":"123","author":"AM Roccaro","year":"2014","unstructured":"Roccaro AM, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, et al. C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120\u201331.","journal-title":"Blood."},{"key":"1762_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/leu.2014.187","volume":"29","author":"Y Cao","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, et al. The WHIM-like CXCR4 S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s macroglobulinemia. Leukemia. 2015;29:169\u201376.","journal-title":"Leukemia."},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1182\/bloodadvances.2021006106","volume":"6","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, et al. Response and survival predictors in a cohort of 319 patients with Waldenstr\u00f6m macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022;6:1015\u201324.","journal-title":"Blood Adv"},{"key":"1762_CR23","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/bjh.15049","volume":"180","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180:374\u201380.","journal-title":"Br J Haematol"},{"key":"1762_CR24","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","volume":"69","author":"E Braggio","year":"2009","unstructured":"Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kB signaling pathways in Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Res. 2009;69:3579\u201388.","journal-title":"Cancer Res"},{"key":"1762_CR25","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood.V100.8.2996","volume":"100","author":"RFJ Schop","year":"2002","unstructured":"Schop RFJ, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, et al. Waldenstr\u00f6m macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100:2996\u20133001.","journal-title":"Blood."},{"key":"1762_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.17028","volume":"192","author":"R Garc\u00eda-Sanz","year":"2021","unstructured":"Garc\u00eda-Sanz R, Dogliotti I, Zaccaria GM, Ocio EM, Rubio A, Murillo I, et al. 6q deletion in Waldenstr\u00f6m macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2021;192:843\u201352.","journal-title":"Br J Haematol"},{"key":"1762_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/ajh.26339","volume":"96","author":"D Krzisch","year":"2021","unstructured":"Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F, et al. Cytogenetic and molecular abnormalities in Waldenstr\u00f6m\u2019s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol. 2021;96:1569\u201379.","journal-title":"Am J Hematol"},{"key":"1762_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjh.15560","volume":"184","author":"JN Gustine","year":"2019","unstructured":"Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, et al. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2019;184:242\u20135.","journal-title":"Br J Haematol"},{"key":"1762_CR29","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","volume":"23","author":"S Poulain","year":"2017","unstructured":"Poulain S, Roumier C, Bertrand E, Renneville A, Caillault-Venet A, Doye E, et al. TP53 mutation and its prognostic significance in Waldenstrom\u2019s macroglobulinemia. Clin Cancer Res. 2017;23:6325\u201336.","journal-title":"Clin Cancer Res"},{"key":"1762_CR30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","volume":"102","author":"M Varettoni","year":"2017","unstructured":"Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102:2077\u201385.","journal-title":"Haematologica."},{"key":"1762_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med"},{"key":"1762_CR32","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","volume":"107","author":"J Khwaja","year":"2022","unstructured":"Khwaja J, D\u2019Sa S, Minnema MC, Kersten MJ, Wechalekar A, Vos JM. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 2022;107:2037\u201350.","journal-title":"Haematologica"},{"key":"1762_CR33","doi-asserted-by":"crossref","unstructured":"Puig N, Ocio EM, Jim\u00e9nez C, Paiva B, Miguel JFS, Garc\u00eda-Sanz R. Waldenstr\u00f6m\u2019s macroglobulinemia immunophenotype. In: Leblond V, Treon S, Dimoploulos M, editors. Waldenstr\u00f6m\u2019s Macroglobulinemia. Springer, Cham; 2017. p. 21\u201334.","DOI":"10.1007\/978-3-319-22584-5_2"},{"key":"1762_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bjh.13091","volume":"168","author":"M Varettoni","year":"2015","unstructured":"Varettoni M, Arcaini L, Rattotti S, Ferretti V, Cazzola M. Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. Br J Haematol. 2015;168:301\u20132.","journal-title":"Br J Haematol"},{"key":"1762_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pathol.2019.11.002","volume":"52","author":"MG Maqbool","year":"2020","unstructured":"Maqbool MG, Tam CS, Morison IM, Simpson D, Mollee P, Schneider H, et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenstr\u00f6m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Disease. Pathology. 2020;52:167\u201378.","journal-title":"Pathology."},{"key":"1762_CR36","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, Van Der Velden VHJ, Martin-Ayuso M, B\u00f6ttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010.","journal-title":"Leukemia."},{"key":"1762_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/10428194.2021.2018584","volume":"63","author":"K Amaador","year":"2022","unstructured":"Amaador K, Vos JMI, Pals ST, Kraan W, Dobber JA, Minnema MC, et al. Discriminating between Waldenstr\u00f6m macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Leuk Lymphoma. 2022;63:1070\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1762_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bjh.13361","volume":"169","author":"J Schmidt","year":"2015","unstructured":"Schmidt J, Federmann B, Schindler N, Steinhilber J, Bonzheim I, Fend F, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169:795\u2013803.","journal-title":"Br J Haematol"},{"key":"1762_CR39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","volume":"33","author":"S Zanwar","year":"2019","unstructured":"Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, et al. Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia. Leukemia. 2019;33:790\u20134.","journal-title":"Leukemia."},{"key":"1762_CR40","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/leu.2014.65","volume":"28","author":"L Xu","year":"2014","unstructured":"Xu L, Hunter ZR, Yang G, Cao Y, Liu X, Manning R, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenstr\u00f6m\u2019s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014;28:1698\u2013704.","journal-title":"Leukemia."},{"key":"1762_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3324\/haematol.2016.147728","volume":"102","author":"MC Minnema","year":"2017","unstructured":"Minnema MC, Kimby E, D\u2019Sa S, Fornecker LM, Poulain S, Snijders TJ, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017;102:43\u201351.","journal-title":"Haematologica."},{"key":"1762_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/bjh.13078","volume":"167","author":"S Poulain","year":"2014","unstructured":"Poulain S, Boyle EM, Roumier C, Demarquette H, Wemeau M, Geffroy S, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014;167:506\u201313.","journal-title":"Br J Haematol"},{"key":"1762_CR43","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1182\/blood-2013-11-537993","volume":"123","author":"C Mu\u00f1iz","year":"2014","unstructured":"Mu\u00f1iz C, Mart\u00edn-Mart\u00edn L, L\u00f3pez A, S\u00e1nchez-Gonz\u00e1lez B, Salar A, Almeida J, et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood. 2014;123:1864\u20139.","journal-title":"Blood."},{"key":"1762_CR44","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","volume":"103","author":"D Drandi","year":"2018","unstructured":"Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jim\u00e9nez C, Guerrini F, et al. Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia. Haematologica. 2018;103:1029\u201337.","journal-title":"Haematologica."},{"key":"1762_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hon.2489","volume":"36","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, et al. The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol. 2018;36:429\u201335.","journal-title":"Hematol Oncol"},{"key":"1762_CR46","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, Corchete LA, Vidriales M-B, Garcia-Sanz R, Perez JJ, Aires-Mejia I, et al. The cellular origin and malignant transformation of Waldenstrom macroglobulinemia. Blood. 2015;125:2370\u201380.","journal-title":"Blood."},{"key":"1762_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/cyto.b.20429","volume":"76","author":"MR Loken","year":"2009","unstructured":"Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytom Part B Clin Cytom. 2009;76:27\u201336.","journal-title":"Cytom Part B Clin Cytom"},{"key":"1762_CR48","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5045\/br.2013.48.4.300","volume":"48","author":"G D\u2019Angelo","year":"2013","unstructured":"D\u2019Angelo G, Hotz AM, Monti M. Lymphoplasmacytic non-Hodgkin lymphoma\/Waldenstr\u00f6m\u2019s macroglobulinemia with CD5+, CD23+, and CD10-. Blood Res. 2013;48:300\u20133.","journal-title":"Blood Res"},{"key":"1762_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pathol.2017.02.004","volume":"49","author":"A El-Ayoubi","year":"2017","unstructured":"El-Ayoubi A, Wang JQ, Hein N, Talaulikar D. Role of plasma cells in Waldenstr\u00f6m macroglobulinaemia. Pathology. 2017;49:337\u201345.","journal-title":"Pathology."},{"key":"1762_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clinbiochem.2012.11.007","volume":"46","author":"CZ Wang","year":"2013","unstructured":"Wang CZ, Lin J, Qian J, Shao R, Xue D, Qian W, et al. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. Clin Biochem. 2013;46:385\u20137.","journal-title":"Clin Biochem"},{"key":"1762_CR51","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/PAI.0000000000000020","volume":"22","author":"C Jim\u00e9nez","year":"2014","unstructured":"Jim\u00e9nez C, Chill\u00f3n MC, Balanzategui A, Puig N, Sebasti\u00e1n E, Alcoceba M, et al. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2014;22:768\u201373.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1762_CR52","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ajh.23545","volume":"88","author":"S Poulain","year":"2013","unstructured":"Poulain S, Roumier C, Gali\u00e8gue-Zouitina S, Daudignon A, Herbaux C, Aiijou R, et al. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol. 2013;88:948\u201354.","journal-title":"Am J Hematol"},{"key":"1762_CR53","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1038\/s41375-018-0197-7","volume":"32","author":"T Bagratuni","year":"2018","unstructured":"Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia. 2018;32:2617\u201325.","journal-title":"Leukemia."},{"key":"1762_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.15792","volume":"186","author":"E Willenbacher","year":"2019","unstructured":"Willenbacher E, Willenbacher W, Wolf DG, Zelger B, Peschel I, Manzl C, et al. Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88 L265P detection in lymphomas with plasmacytic\/plasmacytoid differentiation. Br J Haematol. 2019;186:189\u201391.","journal-title":"Br J Haematol"},{"key":"1762_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;373:584\u20136.","journal-title":"N Engl J Med"},{"key":"1762_CR56","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2016.146126","volume":"101","author":"A Malecka","year":"2016","unstructured":"Malecka A, Tr\u00f8en G, Tierens A, \u00d8stlie I, Malecki J, Randen U, et al. Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica. 2016;101:e361\u20134.","journal-title":"Haematologica."},{"key":"1762_CR57","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","volume":"22","author":"S Poulain","year":"2016","unstructured":"Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, et al. Genomic landscape of CXCR4 mutations in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res. 2016;22:1480\u20138.","journal-title":"Clin Cancer Res"},{"key":"1762_CR58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/jcm7090288","volume":"7","author":"I Dogliotti","year":"2018","unstructured":"Dogliotti I, Drandi D, Genuardi E, Ferrero S. New molecular technologies for minimal residual disease evaluation in B-cell lymphoid malignancies. J Clin Med. 2018;7:288.","journal-title":"J Clin Med"},{"key":"1762_CR59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/diagnostics11050779","volume":"11","author":"M Ferrante","year":"2021","unstructured":"Ferrante M, Furlan D, Zibellini S, Borriero M, Candido C, Sahnane N, et al. MYD88 L265P detection in IgM monoclonal gammopathies: methodological considerations for routine implementation. Diagnostics. 2021;11:779.","journal-title":"Diagnostics."},{"key":"1762_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1182\/bloodadvances.2021005354","volume":"6","author":"T Bagratuni","year":"2022","unstructured":"Bagratuni T, Markou A, Patseas D, Mavrianou-Koutsoukou N, Aktypi F, Liacos CI, et al. Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Adv. 2022;6:189\u201399.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01762-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01762-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T15:05:30Z","timestamp":1675523130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01762-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01762-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2068231\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,26]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ID, CJ, MV, TB, MF, JP, DD, NP, MG, MG-A, RO, WJ, AT, VL, SP, CK, and FF declared no conflicts of interests related to this publication. DT has received honoraria from Amgen, Novartis, Roche, BeiGene, Janssen, Antengene, CSL and EUSA; has participated in advisory boards for Roche, Janssen, Antengene, CSL, BeiGene and EUSA; received research funding from Roche and Janssen. EK has received honoraria from Amgen, Genesis Pharma, Janssen, Takeda, GSK, Pfizer; has participated in advisory boards for Janssen, GSK; received research funding from Amgen, Janssen, and received travel and accommodations reimbursement from Janssen, GSK and Sanofi. MJK has received honoraria from Celgene\/BMS, Roche, Kite\/Gilead, Novartis, Miltenyi Biotec and Adicet Bio (all to institution) and research support from Kite\/Gilead (to institution). SDS received honoraria from BeiGene, Janssen, and Sanofi; was a consultant\/advisor for Janssen, BeiGene and Sanofi; received research funding from Janssen and received travel and accommodations reimbursement from Janssen, BeiGene and Sanofi. MK has received honoraria from Eusa Pharma, Janssen, Novartis, Roche, and Takeda; has participated in advisory boards for Eusa Pharma, Novartis, and Roche; received travel and accommodations reimbursement from Takeda. WW: Steering & Safety Committees AMGEN, Celgene, DSMM, Morphosys; Employee syndena (20%); Advisory Boards AMGEN, BMS\u2014Celgene, EUSA Pharma, Gilead, GSK, Incyte, Janssen, Kite & Consultancies Novartis, Morphosys, Merck, Pfizer, Roche, Sandoz, Sanofi, Takeda; Lectures AMGEN, Abbvie, BMS\u2014Celgene, EUSA Pharma, Fujimoto, Gilead, GSK, Incyte, Janssen, Myelom-und Lymphomselbsthilfe \u00d6sterreich, Novartis, Pfizer, Roche, Sandoz, Sanofi, Takeda; Research Funding AMGEN, BMS, Celgene, Janssen, Novartis, Roche, Sanofi, Takeda oncotyrol; European Commission (FP7\u2014OPTATIO) Bundesland Tirol Programm: \u201cTranslational research\u201d. AMR: Research funding from AstraZeneca, European Hematology Association, Transcan2-ERANET\/FRRB, Italian Association for Cancer Research (Fondazione AIRC). Honoraria from: Amgen, Celgene, Takeda, Janssen. PM has received honoraria from BeiGene, AstraZeneca and Janssen; was consultant\/advisor for BeiGene, and Janssen. JMIV: travel and accommodations reimbursement from Celgene, has participated in an advisory board and as a consultant for Sanofi, and received research support (institutional) from BeiGene. MAD: honoraria from ABBVIE and Janssen; consultant\/advisor for AstraZeneca, BeiGene, Janssen; travel and accommodation reimbursement from ABBVIE, AstraZeneca, BeiGene, Janssen. CB: Consultancy: Pfizer, AbbVie, Novartis, Janssen, BeiGene, Roche, Incyte, BMS, Celgene; Morphosys; Research funding: Roche, Janssen, AbbVie, Amgen, Bayer, Celltrion, Pfizer, MSD. SF: Janssen (Consultancy, Advisory board, Speakers honoraria, Research funding); EUSA Pharma (Consultancy, Advisory board, Speakers honoraria); Gilead, Morphosys (Research funding); Incyte, Clinigen (Advisory board); Servier, Gentili (Speakers honoraria). RG-S has received honoraria from Amgen, BeiGene, Janssen, and Takeda; was a consultant\/advisor for Janssen; received research funding from Gilead; holds patents, royalties, or other intellectual property from BIOMED 2 Primers, and received travel and accommodations reimbursement from Janssen and Takeda. RG-S is the current president of the Spanish Society of Hematology and Hemotherapy (\n                      \n                      ).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}